Research ExplorerPublications[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikat...

[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren

Standard

[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren. / Pfannenberg, A C; Oechsle, K; Kollmannsberger, C; Dohmen, B M; Bokemeyer, C; Bares, R; Vontheim, R; Claussen, C D.

In: ROFO-FORTSCHR RONTG, Vol. 176, No. 1, 01.2004, p. 76-84.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pfannenberg, AC, Oechsle, K, Kollmannsberger, C, Dohmen, BM, Bokemeyer, C, Bares, R, Vontheim, R & Claussen, CD 2004, '[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren', ROFO-FORTSCHR RONTG, vol. 176, no. 1, pp. 76-84. https://doi.org/10.1055/s-2004-814665

APA

Pfannenberg, A. C., Oechsle, K., Kollmannsberger, C., Dohmen, B. M., Bokemeyer, C., Bares, R., Vontheim, R., & Claussen, C. D. (2004). [ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren. ROFO-FORTSCHR RONTG, 176(1), 76-84. https://doi.org/10.1055/s-2004-814665

Vancouver

Pfannenberg AC, Oechsle K, Kollmannsberger C, Dohmen BM, Bokemeyer C, Bares R et al. [ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren. ROFO-FORTSCHR RONTG. 2004 Jan;176(1):76-84. https://doi.org/10.1055/s-2004-814665

Bibtex

@article{a3eb1e6f56004381b31789f4bec109f2,
title = "[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als pr{\"a}diktive Indikatoren f{\"u}r das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren",
abstract = "PURPOSE: To assess the ability of [(18)F]FDG-PET, CT/MRI and serum tumor marker (TM) for the early prediction of response in patients with metastatic germ cell tumors (GCT) undergoing salvage high-dose chemotherapy (HD-CTX).MATERIALS AND METHODS: Before commencement of HD-CTX, 19 patients with metastases from GCT were evaluated with [(18)F]FDG-PET, CT or MRI and TM after 2-3 cycles of induction chemotherapy and the results compared with those of the baseline examinations. PET was analyzed visually and quantitatively by calculating the standard uptake value (SUV). CT or MRI was evaluated for changes in tumor size (progressive disease/stable disease PD/SD = viable lesion; partial remission/complete remission PR/CR = nonviable lesion), density or signal intensity, homogeneity and contrast enhancement. For the prognosis, the worse case, i.e., the most vital lesion detected in a patient, was considered. The reference standard was the result of the histology after resection of any residual masses (N = 10) and/or the clinical-radiological follow-up for at least 6 months after completion of the treatment (N = 9).RESULTS: Six of nineteen patients (32 %) remained progression-free for over 6 months following treatment, whereas 13 (68 %) progressed. The outcome of HD-CTX was correctly predicted by PET, CT and TM in 89 %, 67 % and 88 %, respectively. In 5 of 6 patients with successful HD-CTX, PET was negative (mean SUV = 1.8), with CT or MRI showing a partial regression of the tumor in 4 of 5 patients. Of the 13 patients not cured by HD-CTX, the PET data were positive in all (mean SUV = 2.7), and the CT/MRI results were true positive (PD or SD) in 8 and false negative (PR) in 5 patients. The combined assessment of CT and TM corrected 3 false negative prognoses and 1 false positive CT prognosis. Two patients with unfavorable outcome despite a favorable response by CT and TM criteria were exclusively identified by PET. The resultant sensitivities and specificities for the prediction of therapy response are as follows: PET 100% and 67%; CT/MRI 62% and 80%; TM 83% and 100%; CT+TM 85% and 83%.CONCLUSION: FDG-PET has a high prognostic value for predicting the response to chemotherapy in patients with metastatic GCT early in the course of treatment and may improve patient selection for subsequent HD-CTX protocols. Especially in patients with response to induction chemotherapy according to CT or TM evaluation, PET offers additional information to detect patients with an overall unfavorable outcome.",
keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols, Chorionic Gonadotropin, beta Subunit, Human, Fluorodeoxyglucose F18, Follow-Up Studies, Germany, Germinoma, Humans, Karnofsky Performance Status, Logistic Models, Magnetic Resonance Imaging, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Recurrence, Local, Patient Selection, Predictive Value of Tests, Prognosis, Radiopharmaceuticals, Seminoma, Sensitivity and Specificity, Testicular Neoplasms, Time Factors, Tomography, Emission-Computed, Tomography, X-Ray Computed, Tumor Markers, Biological, alpha-Fetoproteins",
author = "Pfannenberg, {A C} and K Oechsle and C Kollmannsberger and Dohmen, {B M} and C Bokemeyer and R Bares and R Vontheim and Claussen, {C D}",
year = "2004",
month = jan,
doi = "10.1055/s-2004-814665",
language = "Deutsch",
volume = "176",
pages = "76--84",
journal = "ROFO-FORTSCHR RONTG",
issn = "1438-9029",
publisher = "Georg Thieme Verlag KG",
number = "1",

}

RIS

TY - JOUR

T1 - [ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren

AU - Pfannenberg, A C

AU - Oechsle, K

AU - Kollmannsberger, C

AU - Dohmen, B M

AU - Bokemeyer, C

AU - Bares, R

AU - Vontheim, R

AU - Claussen, C D

PY - 2004/1

Y1 - 2004/1

N2 - PURPOSE: To assess the ability of [(18)F]FDG-PET, CT/MRI and serum tumor marker (TM) for the early prediction of response in patients with metastatic germ cell tumors (GCT) undergoing salvage high-dose chemotherapy (HD-CTX).MATERIALS AND METHODS: Before commencement of HD-CTX, 19 patients with metastases from GCT were evaluated with [(18)F]FDG-PET, CT or MRI and TM after 2-3 cycles of induction chemotherapy and the results compared with those of the baseline examinations. PET was analyzed visually and quantitatively by calculating the standard uptake value (SUV). CT or MRI was evaluated for changes in tumor size (progressive disease/stable disease PD/SD = viable lesion; partial remission/complete remission PR/CR = nonviable lesion), density or signal intensity, homogeneity and contrast enhancement. For the prognosis, the worse case, i.e., the most vital lesion detected in a patient, was considered. The reference standard was the result of the histology after resection of any residual masses (N = 10) and/or the clinical-radiological follow-up for at least 6 months after completion of the treatment (N = 9).RESULTS: Six of nineteen patients (32 %) remained progression-free for over 6 months following treatment, whereas 13 (68 %) progressed. The outcome of HD-CTX was correctly predicted by PET, CT and TM in 89 %, 67 % and 88 %, respectively. In 5 of 6 patients with successful HD-CTX, PET was negative (mean SUV = 1.8), with CT or MRI showing a partial regression of the tumor in 4 of 5 patients. Of the 13 patients not cured by HD-CTX, the PET data were positive in all (mean SUV = 2.7), and the CT/MRI results were true positive (PD or SD) in 8 and false negative (PR) in 5 patients. The combined assessment of CT and TM corrected 3 false negative prognoses and 1 false positive CT prognosis. Two patients with unfavorable outcome despite a favorable response by CT and TM criteria were exclusively identified by PET. The resultant sensitivities and specificities for the prediction of therapy response are as follows: PET 100% and 67%; CT/MRI 62% and 80%; TM 83% and 100%; CT+TM 85% and 83%.CONCLUSION: FDG-PET has a high prognostic value for predicting the response to chemotherapy in patients with metastatic GCT early in the course of treatment and may improve patient selection for subsequent HD-CTX protocols. Especially in patients with response to induction chemotherapy according to CT or TM evaluation, PET offers additional information to detect patients with an overall unfavorable outcome.

AB - PURPOSE: To assess the ability of [(18)F]FDG-PET, CT/MRI and serum tumor marker (TM) for the early prediction of response in patients with metastatic germ cell tumors (GCT) undergoing salvage high-dose chemotherapy (HD-CTX).MATERIALS AND METHODS: Before commencement of HD-CTX, 19 patients with metastases from GCT were evaluated with [(18)F]FDG-PET, CT or MRI and TM after 2-3 cycles of induction chemotherapy and the results compared with those of the baseline examinations. PET was analyzed visually and quantitatively by calculating the standard uptake value (SUV). CT or MRI was evaluated for changes in tumor size (progressive disease/stable disease PD/SD = viable lesion; partial remission/complete remission PR/CR = nonviable lesion), density or signal intensity, homogeneity and contrast enhancement. For the prognosis, the worse case, i.e., the most vital lesion detected in a patient, was considered. The reference standard was the result of the histology after resection of any residual masses (N = 10) and/or the clinical-radiological follow-up for at least 6 months after completion of the treatment (N = 9).RESULTS: Six of nineteen patients (32 %) remained progression-free for over 6 months following treatment, whereas 13 (68 %) progressed. The outcome of HD-CTX was correctly predicted by PET, CT and TM in 89 %, 67 % and 88 %, respectively. In 5 of 6 patients with successful HD-CTX, PET was negative (mean SUV = 1.8), with CT or MRI showing a partial regression of the tumor in 4 of 5 patients. Of the 13 patients not cured by HD-CTX, the PET data were positive in all (mean SUV = 2.7), and the CT/MRI results were true positive (PD or SD) in 8 and false negative (PR) in 5 patients. The combined assessment of CT and TM corrected 3 false negative prognoses and 1 false positive CT prognosis. Two patients with unfavorable outcome despite a favorable response by CT and TM criteria were exclusively identified by PET. The resultant sensitivities and specificities for the prediction of therapy response are as follows: PET 100% and 67%; CT/MRI 62% and 80%; TM 83% and 100%; CT+TM 85% and 83%.CONCLUSION: FDG-PET has a high prognostic value for predicting the response to chemotherapy in patients with metastatic GCT early in the course of treatment and may improve patient selection for subsequent HD-CTX protocols. Especially in patients with response to induction chemotherapy according to CT or TM evaluation, PET offers additional information to detect patients with an overall unfavorable outcome.

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Chorionic Gonadotropin, beta Subunit, Human

KW - Fluorodeoxyglucose F18

KW - Follow-Up Studies

KW - Germany

KW - Germinoma

KW - Humans

KW - Karnofsky Performance Status

KW - Logistic Models

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multicenter Studies as Topic

KW - Neoplasm Recurrence, Local

KW - Patient Selection

KW - Predictive Value of Tests

KW - Prognosis

KW - Radiopharmaceuticals

KW - Seminoma

KW - Sensitivity and Specificity

KW - Testicular Neoplasms

KW - Time Factors

KW - Tomography, Emission-Computed

KW - Tomography, X-Ray Computed

KW - Tumor Markers, Biological

KW - alpha-Fetoproteins

U2 - 10.1055/s-2004-814665

DO - 10.1055/s-2004-814665

M3 - SCORING: Zeitschriftenaufsatz

C2 - 14712410

VL - 176

SP - 76

EP - 84

JO - ROFO-FORTSCHR RONTG

JF - ROFO-FORTSCHR RONTG

SN - 1438-9029

IS - 1

ER -